NASDAQ:PMD Psychemedics (PMD) Stock Forecast, Price & News $4.86 +0.01 (+0.21%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$4.76▼$5.0150-Day Range$4.69▼$5.6052-Week Range$4.67▼$6.94Volume37,015 shsAverage Volume6,624 shsMarket Capitalization$27.80 millionP/E RatioN/ADividend Yield5.76%Price TargetN/A ProfileProfileChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Psychemedics (NASDAQ:PMD) StockPsychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.Read More Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address PMD Stock News HeadlinesMay 23, 2023 | americanbankingnews.comPsychemedics Co. Plans Quarterly Dividend of $0.07 (NASDAQ:PMD)May 19, 2023 | msn.comPsychemedics's Ex-Dividend Date Is Wednesday, Here's What You Need To KnowJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 19, 2023 | finance.yahoo.comDo These 3 Checks Before Buying Psychemedics Corporation (NASDAQ:PMD) For Its Upcoming DividendMay 13, 2023 | finance.yahoo.comPsychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07May 12, 2023 | msn.comPsychemedics (PMD) Declares $0.07 DividendMay 10, 2023 | msn.comPsychemedics declares $0.07 dividendMay 9, 2023 | finance.yahoo.comPsychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash DividendJune 8, 2023 | MarketBeat Internal (Ad)Introducing MarketBeat All AccessGet real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.April 17, 2023 | finance.yahoo.comQuite a few insiders invested in Psychemedics Corporation (NASDAQ:PMD) last year which is positive news for shareholdersMarch 21, 2023 | finance.yahoo.comPsychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash DividendJanuary 5, 2023 | reuters.comPMD.PH - Psychemedics Corp. | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comPsychemedics Corporation (PMD) Stock Historical Prices & Data - Yahoo FinanceNovember 12, 2022 | finance.yahoo.comPsychemedics Third Quarter 2022 Earnings: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)November 9, 2022 | finance.yahoo.comPsychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash DividendNovember 7, 2022 | finance.yahoo.comOne Psychemedics Corporation (NASDAQ:PMD) insider upped their stake by 13% in the previous yearOctober 4, 2022 | reuters.comPMD.O - Psychemedics Corp. | Stock Price & Latest News | ReutersSeptember 8, 2022 | reuters.comPMD.OQ - Psychemedics Corp. | Stock Price & Latest News | ReutersAugust 19, 2022 | nasdaq.comDon't Buy Psychemedics Corporation (NASDAQ:PMD) For Its Next Dividend Without Doing These Checks - NasdaqAugust 18, 2022 | finance.yahoo.comDon't Race Out To Buy Psychemedics Corporation (NASDAQ:PMD) Just Because It's Going Ex-DividendAugust 17, 2022 | marketscreener.comPSYCHEMEDICS CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.comAugust 11, 2022 | streetinsider.comForm 10-Q PSYCHEMEDICS CORP For: Jun 30 - StreetInsider.comAugust 9, 2022 | greenwichtime.comPsychemedics: Q2 Earnings Snapshot - Greenwich TimeAugust 9, 2022 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash DividendAugust 9, 2022 | globenewswire.comPsychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend - GlobeNewswireAugust 4, 2022 | gurufocus.comTieton Capital Management, LLC Buys Guess? Inc, Fluent Inc, BM Technologies Inc, Sells , Trecora Resources, Insight Enterprises Inc - GuruFocus.comJuly 18, 2022 | nz.finance.yahoo.comEliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive DisorderSee More Headlines PMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMD Company Calendar Last Earnings3/21/2023Ex-Dividend for 4/10 Dividend3/30/2023Dividend Payable4/10/2023Ex-Dividend for 6/8 Dividend5/24/2023Today6/08/2023Dividend Payable6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PMD CUSIPN/A CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees139Year Founded1985Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,080,000.00 Net Margins-6.13% Pretax Margin-6.62% Return on Equity-13.52% Return on Assets-7.77% Debt Debt-to-Equity Ratio0.02 Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$24.59 million Price / Sales1.12 Cash Flow$0.39 per share Price / Cash Flow12.24 Book Value$1.91 per share Price / Book2.52Miscellaneous Outstanding Shares5,721,000Free Float4,937,000Market Cap$27.52 million OptionableNot Optionable Beta0.60 Social Links Key ExecutivesRaymond C. KubackiChairman, President & Chief Executive OfficerCharles M. DoucotExecutive Vice PresidentMichael I. SchafferVice President-Laboratory OperationsWilliam B. NorrisControllerPatrick J. KinneySecretaryKey CompetitorsCentogeneNASDAQ:CNTGAkuminNASDAQ:AKUAmerican Shared Hospital ServicesNYSE:AMSAclarionNASDAQ:ACONExagenNASDAQ:XGNView All CompetitorsInstitutional OwnershipAncora Advisors LLCBought 7,457 shares on 5/16/2023Ownership: 1.370%Renaissance Technologies LLCSold 9,200 shares on 5/12/2023Ownership: 4.947%BlackRock Inc.Sold 8,087 shares on 5/12/2023Ownership: 1.375%Dimensional Fund Advisors LPSold 2,354 shares on 5/12/2023Ownership: 0.995%View All Institutional Transactions PMD Stock - Frequently Asked Questions How have PMD shares performed in 2023? Psychemedics' stock was trading at $4.9047 on January 1st, 2023. Since then, PMD shares have decreased by 1.9% and is now trading at $4.81. View the best growth stocks for 2023 here. Are investors shorting Psychemedics? Psychemedics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,700 shares, an increase of 24.5% from the April 30th total of 9,400 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is presently 1.7 days. Approximately 0.3% of the company's stock are sold short. View Psychemedics' Short Interest. When is Psychemedics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our PMD earnings forecast. How were Psychemedics' earnings last quarter? Psychemedics Co. (NASDAQ:PMD) released its earnings results on Tuesday, March, 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. The company earned $5.70 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 13.52% and a negative net margin of 6.13%. How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics? Psychemedics announced a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be given a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 annualized dividend and a yield of 5.82%. The ex-dividend date is Wednesday, May 24th. Read our dividend analysis for PMD. Is Psychemedics a good dividend stock? Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 5.97%. PMD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for PMD. What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO? 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG). What is Psychemedics' stock symbol? Psychemedics trades on the NASDAQ under the ticker symbol "PMD." Who are Psychemedics' major shareholders? Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.95%), Ancora Advisors LLC (1.37%), BlackRock Inc. (1.38%) and Dimensional Fund Advisors LP (0.99%). Insiders that own company stock include Fred J Weinert, Michael I Schaffer, Peter Kamin and Raymond C Kubacki Jr. View institutional ownership trends. How do I buy shares of Psychemedics? Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Psychemedics' stock price today? One share of PMD stock can currently be purchased for approximately $4.81. How much money does Psychemedics make? Psychemedics (NASDAQ:PMD) has a market capitalization of $27.52 million and generates $24.59 million in revenue each year. The company earns $-1,080,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. How many employees does Psychemedics have? The company employs 139 workers across the globe. How can I contact Psychemedics? Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The official website for the company is www.psychemedics.com. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236. This page (NASDAQ:PMD) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.